Sun Pharma Gets Partial Relief From US Court In Litigation Involving Delay In Launch Of 3 Generic Drugs In US Market
[ By Bobby Anthony ]Drug maker Sun Pharma has informed stock exchanges that it has received a partial relief from a US court in a litigation alleging delay by the company in launching three generic drugs in the US market.The Mumbai-based company happens to be a defendant in a multi-district litigation brought by various classes of plaintiffs in the US District Court (District of...
ToRead the Full Story, Subscribe to
Access the exclusive LEGAL ERAStories,Editorial and Expert Opinion
Drug maker Sun Pharma has informed stock exchanges that it has received a partial relief from a US court in a litigation alleging delay by the company in launching three generic drugs in the US market.
The Mumbai-based company happens to be a defendant in a multi-district litigation brought by various classes of plaintiffs in the US District Court (District of Massachusetts), alleging a delay in the market entry of three generic drugs namely Valganciclovir, Valsartan and Esomeprazole.
The company stated that the complaints have asserted claims under the Racketeer Influenced and Corrupt Organizations Act, federal and state antitrust laws, and state consumer protection laws.
Sun Pharma stated that on November 27, 2019, the US District Court (District of Massachusetts) entered a decision denying in part and granting in part the company’s motion to dismiss the claims of certain plaintiffs.
Under the ruling, the majority of those plaintiff's claims would survive and several state law claims have been dismissed, the company stated.
The company also stated that it would continue to vigorously defend against all claims, besides which it is also considering its appeal options about claims which were not dismissed in the latest court decision.
